The role of resistin and adiponectin ratios with uric acid in assessing metabolic syndrome in type 2 diabetes.

Metabolic syndrome (MetS) is a growing global healthcare burden. Patients with type 2 diabetes mellitus (T2DM) are more likely to acquire MetS than the general population. Recent research suggests that the interaction of adipose tissue products, such as adiponectin resistin and uric acid, is essential in MetS onset. To examine the role of resistin and adiponectin ratios with uric acid in predicting MetS onset T2DM patients. In a two-year prospective study, 72 T2DM patients were categorised into MetS and non-MetS, according to MetS development. The levels of resistin, adiponectin, uric acid (UA), fasting glucose, high-density lipoprotein cholesterol, and triglycerides were analysed from serum samples. ROC curves and their corresponding areas under the curve (AUC) were utilised to establish the best cut-off values of biomarkers for distinguishing MetS patients and non-MetS patients. The logistic regression analysis was performed to predict the onset of MetS in patients with T2DM. T2DM patients with and without MetS showed significant differences in resistin/UA (p = 0.017), adiponectin/UA (p < 0.001) and adiponectin levels. The Resistin/UA ROC Curve yielded an AUC of 0.825 (p < 0.001), 86.7% sensitivity and 76.2% specificity at a cut-off point of 0.99. Multivariable logistic regression analysis identified resistin /UA ratio [OR 8.631 95% CI 0.450-165.42; p = 0.001] and adiponectin/UA ratio [OR 0.022 95% CI 0.003-0.188; p < 0.001] as independent predictors of MetS. This study confirms the role of resistin-uric acid and adiponectin-uric acid ratios as predictors of MetS development in T2DM patients.